Griffith University researchers have found that naltrexone, typically used for opioid dependency, may treat long COVID and ME/CFS by targeting faulty proteins and restoring ion channel function in immune cells.

The NIH's RECOVER Initiative is initiating clinical trials with 1,660 participants across 50 sites to explore treatments for long COVID, including FDA-approved drugs, melatonin, light therapy, and rehabilitation strategies.

The FDA has delayed an advisory committee meeting on COVID vaccines until June 5 to gather additional data, particularly on the dominant JN.1 strain.

The WHO recommends transitioning to a monovalent vaccine targeting the JN.1 strain, following a surge in JN.1 variants with immune-evasive capabilities.

The research is documented in Frontiers in Immunology, and upcoming clinical trials will focus on patients with long COVID and Chronic Fatigue Syndrome to enhance understanding and treatment of these conditions.